Global Severe Hypertriglyceridemia (SHTG) Treatment Market Set to Reach USD 2675.37 Million by 2033 at a 14.3% CAGR Amid Rising Prevalence and Advancements in Therapeutics

Global Severe Hypertriglyceridemia (SHTG) Treatment Market

The global severe hypertriglyceridemia (SHTG) treatment market, which achieved a valuation of USD 615 million in 2022, is projected to experience rapid growth, reaching approximately USD 2675.37 Million by 2033. This expansion represents a strong CAGR of 14.3% over the forecast period from 2023 to 2033, driven by a growing incidence of SHTG cases and advancements in medication manufacturing technologies. Historically, from 2018 to 2022, the market registered a CAGR of 8%, reflecting increased demand for effective treatment solutions.

Severe hypertriglyceridemia is a condition defined by extremely elevated triglyceride levels in the blood, posing significant risks for cardiovascular diseases, including heart attacks and strokes. As awareness grows regarding the health risks associated with high triglyceride levels, healthcare providers and pharmaceutical companies are focusing on delivering advanced therapies to mitigate cardiovascular risks for SHTG patients.

With ongoing investments in research and the development of more targeted therapeutics, the SHTG treatment market is expected to provide enhanced options for patients worldwide, aiming to reduce the burden of cardiovascular events and improve patient outcomes on a global scale.

Severe Hypertriglyceridemia (SHTG) is a medical condition characterized by abnormally high levels of triglycerides in the blood, which can lead to the development of cardiovascular diseases. SHTG is a serious condition that requires prompt treatment to reduce the risk of cardiovascular events such as heart attacks and strokes.

Severe Hypertriglyceridemia (SHTG) Treatment Market refers to the market for pharmaceutical drugs, medical devices, and other products used in the treatment of Severe Hypertriglyceridemia (SHTG).

Which are Some Prominent Drivers of Severe Hypertriglyceridemia (SHTG) Treatment Market?

Increasing prevalence of severe hypertriglyceridemia and technological advancements driving the growth of SHTG treatment market

The global prevalence of SHTG is increasing, with an estimated 40 million people affected worldwide. This increasing prevalence is a major driver of the SHTG treatment market. With the aging of the global population, there is an increasing prevalence of SHTG among the elderly population. This has created a growing demand for SHTG treatment and is driving the growth of the market.

There have been significant technological advancements in the field of SHTG treatment, including the development of new drugs and medical devices, which are driving the growth of the market. There is a growing awareness among patients and healthcare professionals about the risks associated with untreated SHTG. This is leading to earlier diagnosis and treatment, which is driving the growth of the market.

Governments in many countries are taking initiatives to promote awareness about SHTG and to provide better access to SHTG treatment. This is creating a favorable environment for the growth of the market. As healthcare expenditure continues to increase worldwide, more resources are being allocated to the treatment of chronic conditions such as SHTG. This is driving the growth of the market as well.

Market Competition

Key players in the severe hypertriglyceridemia (SHTG) treatment market are Ionis Pharmaceuticals, 89bio, Inc., Arrowhead Pharmaceuticals, Inc., NorthSea Therapeutics B.V., Amryt Pharma, Afimmune Pharmaceutical, Zucara Therapeutics, Novo Nordisk, Adocia and Pfizer Inc.

• Ionis Pharmaceuticals is a biotechnology company that specializes in the discovery and development of RNA-targeted therapies. The company has developed a drug called volanesorsen (brand name Waylivra), which is used in the treatment of Severe Hypertriglyceridemia (SHTG).
• 89bio, Inc. is a biopharmaceutical company that has been developing therapies for the treatment of severe hypertriglyceridemia (SHTG). The company’s lead drug candidate, called BIO89-100, is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed as a potential treatment for SHTG. In preclinical studies, BIO89-100 has been shown to significantly reduce triglyceride levels in animal models of SHTG.

Key Companies Profiled

• Ionis Pharmaceuticals
• 89bio, Inc.
• Arrowhead Pharmaceuticals, Inc.
• NorthSea Therapeutics B.V.
• Amryt Pharma
• Afimmune Pharmaceutical
• Zucara Therapeutics
• Novo Nordisk
• Adocia
• Pfizer Inc.

A Full Report Overview

Key Segments Profiled in the Severe Hypertriglyceridemia (SHTG) Treatment Market Survey

Drug Class:

• Olezarsen
• Pegozafermin
• Epeleuton
• Lomitapide

Drug Delivery Method:

• Oral Route
• Injectable Route

Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube